Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

키워드

참고문헌 (61)

1. Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
2. Frank E, "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
3. Riso LP, "A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy", J Affect Disord, 43, pp.131~142 (1997)
4. Riedel M, "Response and remission criteria in major depression : a validation of current practice", J Psychiatr Res, 44, pp.1063~1068 (2010)
5. McClintock SM, "Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication", J Clin Psychopharmacol, 31, pp.180~186 (2011)
6. Pintor L, "Relapse of major depression after complete and partial remission during a 2-year follow-up", J Affect Disord, 73, pp.237~244 (2003)
7. Xiao L, "Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder : a multicenter study", Psychiatry Res, 261, pp.547~553 (2018)
8. Lin EH, "Low-intensity treatment of depression in primary care: is it problematic?", Gen Hosp Psychiatry, 22, pp.78~83 (2000)
9. Patkar AA, "Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder", CNS Drugs, 27(Suppl 1), pp.S29~S37 (2013)
10. Pae CU, "Aripiprazole as adjunctive therapy for patients with major depressive disorder : overview and implications of clinical trial data", CNS Drugs, 25, pp.109~127 (2011)
11. Marcus RN, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : a multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
12. 배치운, "A Meta-Analysis Comparing Open-Label versus Placebo- Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises", PSYCHIATRY INVESTIGATION, 11(4), pp.371~379 (2014), 대한신경정신의학회[DOI]
13. Lin CH, "Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder : a randomized, double-blind, controlled study", J Clin Psychopharmacol, 31, pp.563~568 (2011)
14. Kamijima K, "Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder : a randomized, double-blind, placebo-controlled study(ADMIRE study)", J Affect Disord, 151, pp.899~905 (2013)
15. Lenze EJ, "Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life : a randomised, double-blind, placebo-controlled trial", Lancet, 386, pp.2404~2412 (2015)
16. Zimmerman M, "A clinically useful depression outcome scale", Compr Psychiatry, 49, pp.131~140 (2008)
17. Nierenberg AA, "Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression", J Clin Psychiatry, 62(Suppl 16), pp.5~9 (2001)
18. Sang Won Jeon, "Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study", Clinical Psychopharmacology and Neuroscience, 15(1), pp.28~34 (2017), 대한정신약물학회[DOI]
19. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
20. Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
21. 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
22. Guy W, "ECDEU assessment manual for psychopharmacology" (1976), US Department of Health, Education, and Welfare, Public Health Service
23. Kroenke K, "The PHQ-15 : validity of a new measure for evaluating the severity of somatic symptoms", Psychosom Med, 64, pp.258~266 (2002)
24. Han C, "Psychometric properties of the Patient Health Questionnaire-15(PHQ-15)for measuring the somatic symptoms of psychiatric outpatients", Psychosomatics, 50, pp.580~585 (2009)
25. Beck AT, "An inventory for measuring clinical anxiety : psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
26. Yook SP, "A clinical study on the Korean version of Beck Anxiety Inventory : comparative study of patient and non-patient", Korean J Clin Psychol, 16, pp.185~197 (1997)
27. Lawrence C, "Association between severity of depression and self-perceived cognitive difficulties among full-time employees", Prim Care Companion CNS Disord, 15, pp.PCC.12m014~ (2013)
28. Lam RW, "Psychometric validation of the Perceived Deficits Questionnaire-Depression(PDQ-D)instrument in US and UK respondents with major depressive disorder", Neuropsychiatr Dis Treat, 14, pp.2861~2877 (2018)
29. 김재민, "Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 14(1), pp.26~32 (2016), 대한정신약물학회
30. Bech P, "Rating scales for psychopathology, health status and quality of life a compendium on documentation in accordance with the DSM-III-R and WHO Systems" (1993), SpringerVerlag
31. Kook SH, "A validation of GHQ", QL-12 to assess the quality of life in patients with schizophrenia : using RMSEA, ECVI, and Rasch model, 2000, pp.19, 587~602
32. Leon AC, "Assessing psychiatric impairment in primary care with the Sheehan Disability Scale", Int J Psychiatry Med, 27, pp.93~105 (1997)
33. 박준영, "한국판 Sheehan Disability Scale의 신뢰도와 타당도 연구", Korean Journal of Clinical Psychology, 29(1), pp.73~81 (2010), 한국임상심리학회
34. Papakostas GI, "Managing partial response or nonresponse:switching, augmentation, and combination strategies for major depressive disorder", J Clin Psychiatry, 70(Suppl 6), pp.16~25 (2009)
35. Romera I, "Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study", Eur Psychiatry, 25, pp.58~65 (2010)
36. Hammer-Helmich L, "Functional impairment in patients with major depressive disorder : the 2-year PERFORM study", Neuropsychiatr Dis Treat, 14, pp.239~249 (2018)
37. Goodnick PJ, "Aripiprazole : profile on efficacy and safety", Expert Opin Pharmacother, 3, pp.1773~1781 (2002)
38. McIntyre RS, "Residual anxiety symptoms in depressed primary care patients", J Psychiatr Pract, 13, pp.125~128 (2007)
39. D’Avanzato C, "Anxiety symptoms among remitted depressed outpatients : prevalence and association with quality of life and psychosocial functioning", J Affect Disord, 151, pp.401~404 (2013)
40. Adson DE, "Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors", J Affect Disord, 86, pp.99~104 (2005)
41. Gonda X, "The role of cognitive dysfunction in the symptoms and remission from depression", Ann Gen Psychiatry, 14, pp.27~ (2015)
42. Judd LL, "Major depressive disorder : a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse", J Affect Disord, 50, pp.97~108 (1998)
43. Jaeger J, "Neurocognitive deficits and disability in major depressive disorder", Psychiatry Res, 145, pp.39~48 (2006)
44. Herrera-Guzmán I, "Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder", J Psychiatr Res, 43, pp.855~863 (2009)
45. Jensen JB, "Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats : evidence for direct 5-HT receptor modulation", Eur Neuropsychopharmacol, 24, pp.148~159 (2014)
46. Kapfhammer HP, "Somatic symptoms in depression", Dialogues Clin Neurosci, 8, pp.227~239 (2006)
47. Hiranyatheb T, "The impact of residual symptoms on relapse and quality of life among Thai depressive patients", Neuropsychiatr Dis Treat, 12, pp.3175~3181 (2016)
48. Kennedy N, "Residual symptoms at remission from depression : impact on long-term outcome", J Affect Disord, 80, pp.135~144 (2004)
49. Woo JM, "Importance of remission and residual somatic symptoms in health-related quality of life among outpatients with major depressive disorder : a cross-sectional study", Health Qual Life Outcomes, 12, pp.188~ (2014)
50. Stahl SM, "Antidepressants and somatic symptoms : therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes", J Clin Psychiatry, 64, pp.745~746 (2003)
51. Blier P, "Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder", J Affect Disord, 128(Suppl 1), pp.S3~S10 (2011)
52. Almeida-Santos AF, "The antipsychotic aripiprazole induces antinociceptive effects : possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors", Eur J Pharmacol, 765, pp.300~306 (2015)
53. Fei L, "Unexpected effect of aripiprazole on nociceptive pain", Ther Adv Psychopharmacol, 2, pp.211~212 (2012)
54. Kasahara S, "Four cases of chronic pain that improved dramatically following low-dose aripiprazole administration", Prim Care Companion CNS Disord, 13, pp.PCC.10l010~ (2011)
55. Nelson JC, "Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression : a post-hoc, pooled analysis of two large, placebo-controlled studies", J Affect Disord, 120, pp.133~140 (2010)
56. Paykel ES, "Residual symptoms after partial remission : an important outcome in depression", Psychol Med, 25, pp.1171~1180 (1995)
57. Battle CL, "Treatment goals of depressed outpatients : a qualitative investigation of goals identified by participants in a depression treatment trial", J Psychiatr Pract, 16, pp.425~430 (2010)
58. McIntyre RS, "Treating to target in major depressive disorder: response to remission to functional recovery", CNS Spectr, 20(Suppl 1), pp.20~30 (2015)
59. Zimmerman M, "Severity classification on the Hamilton Depression Rating Scale", J Affect Disord, 150, pp.384~388 (2013)
60. Reynolds WM, "Reliability and validity of the Hamilton Depression Inventory : a paper-and-pencil version of the Hamilton Depression Rating Scale Clinical Interview", Psychol Assess, 7, pp.472~483 (1995)
61. Li SX, "Residual sleep disturbances in patients remitted from major depressive disorder : a 4-year naturalistic follow-up study", Sleep, 35, pp.1153~1161 (2012)

관련 논문AI추천